Live Breaking News & Updates on Rapt Therapeutics Inc
Stay updated with breaking news from Rapt therapeutics inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Free Report) has received a consensus recommendation of “Hold” from the thirteen analysts that are currently covering the company, Marketbeat Ratings reports. Nine analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month target price among […] ....
RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Free Report) has earned an average rating of “Hold” from the thirteen ratings firms that are currently covering the stock, Marketbeat.com reports. Nine equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective […] ....
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $25.67 Average Target Price from Analysts themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
On the verge of top-line data from its phase IIb trial with oral small-molecule CC chemokine receptor 4 (CCR4) antagonist zelnecirnon in atopic dermatitis (AD), due around the middle of this year, Rapt Therapeutics Inc. said the U.S. FDA has imposed a clinical hold on that study with the otherwise promising drug, also known as RPT-193, in AD as well as the phase IIa trial with the same compound in asthma. ....
RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Free Report) has been given an average recommendation of “Moderate Buy” by the eleven analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The average twelve-month price objective among […] ....